| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-05-24 | Pennvax®-GP | HIV infection | 1 | Inovio Pharmaceuticals (USA - PA) | Infectious diseases |
| 2017-05-23 | Ingrezza® (valbenazine - NBI-98854) | Tourette syndrome | 2 | Neurocrine Biosciences (USA - CA) | Rare diseases - Neurological diseases |
| 2017-05-23 | revefenacin (TD-4208) | chronic obstructive pulmonary disease (COPD) | Mylan (USA - PA) Theravance (UK) | Lung diseases - Respiratory diseases | |
| 2017-05-22 | Nucala® (mepolizumab) | asthma | 3b | GSK (UK) | Inflammatory diseases - Respiratory diseases |
| 2017-05-22 | BGB324 in combination with pembrolizumab or dabrafenib+trametinib | melanoma | 1-2 | BergenBio (Norway) | Cancer - Oncology |
| 2017-05-22 | imeglimin | type 2 diabetes | 1 | Poxel (France) | Metabolic diseases |
| 2017-05-22 | benralizumab | asthma | 3 | AstraZeneca (UK) | Allergic diseases – Inflammatory diseases – Respiratory diseases |
| 2017-05-19 | Betalutin™ (177Lu-Dota-tetulomab) | relapsed CD37 positive non-Hodgkin lymphoma | 1-2 | Nordic Nanovector (Norway) | Cancer - Oncology |
| 2017-05-19 | ADCT-502 | solid tumors with HER2 expression | 1 | ADC Therapeutics (Switzerland) | Cancer - Oncology |
| 2017-05-19 | dusquetide (SGX942) | oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer | 2 | Soligenix (USA - NJ) | Cancer - Oncology |
| 2017-05-18 | CEA-TCB (RO6958688; RG7802) | carcinoembryonic antigen (CEA)-positive solid tumours, including microsatellite stable (MSS) metastatic colorectal cancers (mCRC) that overexpress CEA and progressed after at least two prior chemotherapy regimens | 1 | Roche (Switzerland) | Cancer - Oncology |
| 2017-05-18 | SHP647 (PF-00547659) | ulcerative colitis | 2 | Shire (UK - USA) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2017-05-18 | Ingrezza® (valbenazine - NBI-98854) | tardive dyskinesia | 3 | Neurocrine Biosciences (USA - CA) | Neurological diseases |
| 2017-05-18 | VXM01 | glioblastoma | 1 | Vaximm (Germany) | Cancer - Oncology |
| 2017-05-18 | A4250 ((2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid) | progressive familial intrahepatic cholestasis (PFIC) | 3 | Albireo Pharma (USA - MA) | Rare diseases - Genetic diseases - Liver diseases - Hepatic diseases |
| 2017-05-17 | mepolizumab | eosinophilic granulomatosis with polyangiitis (EGPA) previously known as Churg-Strauss syndrome | 3 | GSK (UK) | Rare diseases |
| 2017-05-17 | MCLA-128 | solid tumors, breast cancer, gastric cancer, ovarian cancer, endometrial cancer, non small cell lung cancer | 1-2 | Merus (The Netherlands) | Cancer - Oncology |
| 2017-05-17 | sarizotan | Rett syndrome | 2 | Newron (Italy) | Rare diseases - Neurodevelopmental diseases |
| 2017-05-17 | AUT00206 | schizophrenia | 1b | Autifony Therapeutics (UK) | CNS diseases - Mental diseases |
| 2017-05-17 | CX-072 in combination with Yervoy® (ipilimumab) or Zelboraf®(vemurafenib) | solid tumors, lymphoma | 1-2 | CytomX Therapeutics (USA - CA) | Cancer - Oncology |
